An open-label study to evaluate the optimal dose of Xeloda [capecitabine] when combined with Eloxatin [oxaliplatin] and pre-operative pelvic irradiation in patients with locally advanced rectal cancer.

Trial Profile

An open-label study to evaluate the optimal dose of Xeloda [capecitabine] when combined with Eloxatin [oxaliplatin] and pre-operative pelvic irradiation in patients with locally advanced rectal cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs Capecitabine; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms SOCRATES
  • Sponsors Roche
  • Most Recent Events

    • 21 Aug 2009 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 01 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top